18f arabinosyl guanine
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2017 (NCT03311672)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06414902 | Early Phase 1 (Phase 1) | Sep 4, 2024 | University of Texas at Houston |
| NCT06457789 | N/A | Jul 31, 2024 | Free University of Amsterdam, National Institutes of Health (NIH) |
| NCT05663710 | Phase 2 | May 30, 2023 | Department of Defense, University of Texas at Houston |
| NCT03367962 | Phase 1 | May 15, 2018 | CellSight Technologies, Inc., Stanford University |
| NCT03311672 | Phase 2 | Nov 26, 2017 | CellSight Technologies, Inc., University of California, San Francisco |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CellSight Technologies, Inc. | For profit | 2 | 1 | 2 | 2017 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
| Free University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2017 |
7 organizations
Page 1 / 1